Details for Patent: 6,617,321

Title:	2-methyl-thieno-benzodiazepine formulation
Abstract:	The invention provides a pharmaceutically acceptable oleaginous or cholesterol microsphere formulation or olanzapine or olanzapine pamoate or solvates thereof. The invention further provides novel olanzapine pamoate salts or solvates thereof.
Inventor(s):	Allen; Douglas J. (Indianapolis, IN), Dekemper; Kurt D. (Franklin, IN), Ferguson; Thomas H. (Greenfield, IN), Garvin; Stuart J. (Plainfield, IN), Murray; Linda C. (Noblesville, IN), Brooks; Norman D. (Greenfield, IN), Bunnell; Charles A. (Lafayette, IN), Mascarenhas; Snehlata S. (Indianapolis, IN), Shinkle; Sharon L. (Indianapolis, IN), Hendriksen; Barry A. (Guildford, GB), Tupper; David E. (Reading, GB), Sanchez-Felix; Manuel V. (Grayshott, GB)
Assignee:	Eli Lilly and Company (Indianapolis, IN)
Filing Date:	May 01, 2002
Application Number:	10/136,887
Claims:	1. A formulation comprising olanzapine pamoate salt or solvate thereof as an active ingredient and one or more carriers selected from the group consisting of an oleaginous carrier or cholesterol microsphere carrier. 2. A formulation as claimed in claim 1 wherein said formulation has a prolonged sustained release of greater than 7 days and a burst release of less than 15% of the active ingredient. 3. A formulation as claimed by claim 2 wherein the formulation further comprises one or more pharmaceutically acceptable excipients. 4. A formulation as claimed by claim 3 wherein the pharmaceutically acceptable excipient is selected from the group consisting of a gelling agent and an antihydration agent. 5. A formulation as claimed in claim 4 comprising olanzapine pamoate monohydrate, triglycerides of the fractionated vegetable fatty acids C8 and C10, and white wax. 6. A formulation as claimed in claim 1 wherein said carrier is oleagenous. 7. A formulation of claim 1 wherein said carrier is selected from the group consisting of nonionic copolymers of propylene oxide and ethylene oxide, cellulosic, gums, polysaccharide gums, vegetable oils, refined fractionated oils, sucrose diacetate hexaisobutyrate, chitosan, lecithin, and polyvinyl pyrrolidone. 8. A formulation as claimed in claim 7 wherein said carrier is selected from the group consisting of nonionic copolymers of propylene oxide and ethylene oxide, cellulosic gums, polysaccharide gums, vegetable oils, and refined fractionated oils. 9. A formulation as claimed in claim 1 wherein the carrier is a cholesterol microparticle. 10. A formulation as claimed in claim 9 wherein the microparticle is a microsphere. 11. A formulation as claimed in claim 9 wherein the cholesterol is selected from the group consisting of cholesterol, cholesterol palmitate, cholesterol oleate, cholesterol stearate, and cholesterol hemisuccinate. 12. A formulation as claimed in claim 9 wherein the microspheres have a particle size of from 20 to 500 .mu.m. 13. A formulation as claimed in claim 12 wherein the particle size is from 30 to 200 .mu.m. 14. A formulation as claimed in claim 13 wherein the particle size is from 40 to 100 .mu.m. 15. A formulation as claimed in claim 9 wherein the microspheres are administered in an oleaginous carrier. 16. A formulation as claimed in claim 15 wherein the oleaginous carrier is selected from the group consisting of nonionic copolymers of propylene oxide and ethylene oxide, cellulosic gums, polysaccharide gums, vegetable oils, and refined fractionated oils. 17. A formulation as claimed in claim 1 wherein the active ingredient is selected from the group consisting of olanzapine pamoate, olanzapine pamoate dimethanolate, olanzapine pamoate monohydrate, olanzapine pamoate THF solvate, bis(olanzapine)pamoate acetone solvate, and bis(olanzapine)pamoate monohydrate. 18. A formulation as claimed in claim 17 wherein the active ingredient is milled. 19. A formulation as claimed in claim 18 wherein the particle size is from 20 to 60 .mu.m. 20. A formulation as claimed in claim 19 wherein the particle size is from 5 to 20 .mu.m. 21. A formulation as claimed in claim 20 wherein the milled particles are less than or equal to 5 .mu.m. 22. A formulation as claimed in claim 17 wherein the active ingredient is olanzapine pamoate monohydrate having a typical x-ray powder diffraction pattern as represented by the following interplanar spacing: 23. A formulation as claimed in claim 17 wherein the active ingredient is bis(olanzapine)monohydrate having a typical x-ray powder diffraction patter as represented by the following interplanar spacing: 24. A formulation comprising olanzapine pamoate salt or solvate thereof as an active ingredient, and one or more carriers. 25. A formulation comprising olanzapine pamoate salt or solvate thereof, and an oleaginous carrier. 26. A formulation comprising olanzapine pamoate salt or solvate thereof, and a cholesterol microsphere carrier.